Charles River Laboratories Cash Flow Statement
CRL / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Charles River Laboratories generated $738M in operating cash flow and $518M in free cash flow in FY2025. Free cash flow margin was 12.9% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$144.3M | $22.2M | $391.0M | $364.3M | $252.0M | $226.4M | $123.4M | $226.4M | $123.4M | $154.8M | $102.8M | $126.7M | $102.8M | $97.9M | $112.6M |
| Depreciation & Amortization | $403.3M | $361.7M | $265.5M | $234.9M | $198.1M | $161.8M | $131.2M | $161.8M | $131.2M | $126.7M | $96.6M | $96.4M | $96.6M | $81.3M | $90.0M |
| Operating Cash Flow | $737.6M | $734.6M | $760.8M | $546.6M | $480.9M | $441.1M | $318.1M | $441.1M | $318.1M | $316.9M | $209.0M | $252.1M | $209.0M | $208.0M | $215.6M |
| Capital Expenditures | $219.2M | $233.0M | $228.8M | $166.6M | $140.5M | $140.1M | $82.4M | $140.1M | $82.4M | $55.3M | $39.2M | $56.9M | $39.2M | $47.5M | $79.9M |
| Free Cash Flow | $518.5M | $501.6M | $532.0M | $380.0M | $340.4M | $301.1M | $235.6M | $301.1M | $235.6M | $261.6M | $169.9M | $195.2M | $169.9M | $160.5M | $135.7M |
| Share Buybacks | $360.7M | $119.2M | $40.7M | $24.0M | $18.1M | $13.8M | $106.9M | $13.8M | $106.9M | $12.3M | $165.9M | $122.0M | $165.9M | $64.2M | $45.9M |
| FCF Margin | 12.9% | 12.4% | 15.0% | 13.0% | 13.0% | 13.3% | 12.7% | 13.3% | 52.9% | 15.6% | 14.6% | 15.0% | 14.6% | 14.2% | 11.6% |